VIR Vir Biotechnology, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Vir Biotechnology, Inc. (VIR) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 23, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 10, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Vir Biotechnology, Inc. (VIR) (SEC CIK 1706431), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model focused on development and commercialization of infectious disease therapeutics
- • New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
Risk Factors
- • Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- • Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
Management Discussion & Analysis
- • Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- • Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: FDA revoked EUA for sotrovimab COVID-19 treatment December 2024, eliminating expected future US revenue from this product
- • Material update: Net loss $395.1M for nine months ended Sept 30, 2025 vs prior $417.4M period; accumulated deficit $1.2B reflects ongoing R&D investment
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CEO Marianne De Backer appointed to additional role of President effective March 4, 2026 — consolidating top executive positions
- • No new compensation terms disclosed, no outside arrangements or conflicts of interest noted
Item 8.01: Other Events
- • Offering closed Feb 27, 2026; 20,294,117 shares sold including full overallotment exercise at $8.50/share
- • Gross proceeds ~$172.5M before underwriting discounts and offering expenses
Annual Reports Archive10-K
AI-powered analysis of Vir Biotechnology, Inc. (VIR) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Vir Biotechnology, Inc. (VIR) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Vir Biotechnology, Inc. (VIR) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $1.6B | $86.2M | $74.2M | $68.6M |
| Operating Income | $833.1M | -$684.3M | -$587.2M | -$479.3M |
| Net Income | $515.8M | -$615.1M | -$522.0M | -$438.0M |
| Op. Margin | 51.6% | -794.0% | -791.3% | -699.2% |
| Net Margin | 31.9% | -713.8% | -703.4% | -638.9% |
| Balance Sheet | ||||
| Total Assets | $2.8B | $1.9B | $1.4B | $1.0B |
| Equity | $2.1B | $1.6B | $1.2B | $765.3M |
| ROE | 24.8% | -38.7% | -45.4% | -57.2% |
Source: XBRL financial data from Vir Biotechnology, Inc. (VIR) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 10, 2026 | — | — | — |
8-K | Mar 4, 2026 | — | Analysis | — |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 23, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 16, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 3, 2024 | Mar 31, 2024 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest VIR SEC filings in 2026?
Vir Biotechnology, Inc. (VIR) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 10, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did VIR file its most recent 10-K annual report?
Vir Biotechnology, Inc. (VIR) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view VIR 10-Q quarterly reports?
Vir Biotechnology, Inc. (VIR)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every VIR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has VIR filed recently?
Vir Biotechnology, Inc. (VIR)'s most recent 8-K was filed on April 10, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find VIR insider trading activity (Form 4)?
SignalX aggregates every VIR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does VIR file with the SEC?
Vir Biotechnology, Inc. (VIR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VIR filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vir Biotechnology, Inc. (VIR).
What is VIR's SEC CIK number?
Vir Biotechnology, Inc. (VIR)'s SEC CIK (Central Index Key) number is 1706431. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1706431 to look up all VIR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find VIR return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Vir Biotechnology, Inc. (VIR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Vir Biotechnology, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.